In the last 6 years, 16 cases of benign prostatic hyperplasia”>prostatic hyperplasia (BPH) and superficial bladder tumors were treated by simultaneous transurethral electrodesis with satisfactory results. The results are reported as follows. Data and methods Sixteen cases were in this group. All 16 cases had symptoms of dyspareunia, 13 cases had painless hematuria, and the duration of dyspareunia was (5.4±3.7) years; the duration of hematuria was (1.8±1.3) months. There were 10 cases of initial bladder tumors and 6 cases of recurrence. There were 12 cases with single tumor and 4 cases with multiple tumors. The tumor diameter was 0.6-3.5 cm. clinical stage: Ta in 4 cases, T1 in 9 cases, T2 in 3 cases. Pathological grading: 12 cases of G1 and 4 cases of G2 metastatic cell carcinoma of the bladder. The international prostate symptom score was 25.8 ± 4.3, quality of life score 4.6 ± 0.8; maximum urinary flow rate (7.7 ± 4.6) ml/s; estimated weight of prostate volume measured by ultrasound was 25-125 g; remaining urine volume (100.8 ± 82.0) ml. urinary retention occurred and catheter was left in 3 cases. Urinary tract infection was combined in 3 cases. Preoperative diagnosis of bladder tumor was made in 14 cases, and in the other 2 cases, bladder tumor was found during electrodesection of prostate and treated accordingly. The group had 3 cases of coronary heart disease and hypertension, 2 cases of bronchitis and emphysema and pulmonary heart disease, and 1 case of multiple lacunar cerebral infarction. Surgical methods Epidural anesthesia was attached. The electrodesiccope was inserted to observe the position of the bladder and ureter opening, the degree of prostate protrusion into the bladder, to understand the status and size of the hyperplastic prostate, the anatomical relationship between the prostate and the seminal fossa, the condition of the posterior urethra, and to measure the distance from the bladder neck to the seminal fossa. Electrodesiccation steps: Firstly, 2mg mitomycin C or 0.25mg 5-fluorouracil + saline 5ml was injected in multiple places at the base of the tumor to make the base of the tumor float. The tumors in this group all had tissues with diameters of 0.5 to 1.5 cm. When electrodesiccating the bladder tumors, the tumors were rinsed with distilled water and the base of the tumors were excised up to the deep muscle layer to reveal the normal muscle fiber tissue, and the bladder mucosa of 1 to 2 cm around the tumors should be treated with electrocautery after electrodesiccation, and anti-cancer drugs were injected again at the base. The tumor is then electrocuted and the prostate is then electrocuted. For electrodesiccation of the prostate, 3% to 4% mannitol was used as the irrigation solution. After the surgery, a three-chamber balloon catheter was left in place and the catheter was removed after 2 to 3 days of continuous bladder irrigation with saline. Intravesical instillation of anticancer drugs or immune agents was started 3 to 5 days after surgery. In this group, mitomycin C instillation was used in 9 cases, thiotepa instillation in 4 cases, and BCG instillation in 3 cases. Regular follow-ups were conducted. Results In this group, 13 cases were followed up. The average follow-up was (3.2±2.2) years. All patients were able to urinate spontaneously. The prostatic symptom score decreased from 25.8±4.3 before surgery to 4.8±2.6 (P<0.01); the quality of life score decreased from 4.6±0.8 to 1.1±1.0 (P<0.01); the remaining urine volume decreased from (100.8±82) ml to (19.8±15.1) ml (P<0.01); the maximum urine flow rate increased from (7.7±4.6) ml/s to (20.8) ml/s. up to (20.8±3.6)ml/s (P<0.01). Cystoscopy was reviewed regularly after surgery and recurrence was observed in 4 cases, at 4, 8 and 15 months postoperatively, respectively. The site of recurrence was not in the prostatic fossa or posterior urethra. three cases of recurrence were positive for MDR1-mRMA. Discussion Bladder tumors and BPH develop concurrently in about 7% of cases [1-5]. Clinical studies have concluded that there is no problem of tumor implantation when both procedures are performed simultaneously. Some scholars have also retrospectively investigated patients who underwent suprapubic transcatheter prostate removal and bladder tumor resection at the same time, with a follow-up of 1-7 years and regular urine cytology and cystoscopy, and found that bladder neck recurrence accounted for 34.8% of recurrences. It was suggested to be related to the implantation of bladder tumor in the prostatic fossa after simultaneous prostate removal. There were 4 recurrences in our group who underwent transurethral resection of bladder tumor, among which 3 cases were positive for MDR1-mRMA, suggesting that tumor recurrence may be related to the expression of multidrug resistance genes. The use of ">simultaneous electrosurgery for bladder cancer and BPH”>prostatic hyperplasia is indicated for elderly frail patients with combined multi-organ disease and superficial bladder tumors. It is best to inject anti-cancer drugs at the base of the tumor before the bladder tumor electrodesection to increase the safety of electrodesection. Distilled water flushing solution should be used for electrodesiccation of tumor, while mannitol should be used for electrodesiccation of prostate, which can not only increase the effect of killing tumor, but also prevent the occurrence of transurethral electrodesiccation syndrome. After tumor removal, the excised tumor tissue fragments should be flushed and cleaned before TURP is performed.